Cargando…
Vulnerability to low-dose combination of irinotecan and niraparib in ATM-mutated colorectal cancer
BACKGROUND: Despite the advancements in new therapies for colorectal cancer (CRC), chemotherapy still constitutes the mainstay of the medical treatment. For this reason, new strategies to increase the efficacy of chemotherapy are desirable. Poly-ADP-Ribose Polymerase inhibitors (PARPi) have shown to...
Autores principales: | Vitiello, Pietro Paolo, Martini, Giulia, Mele, Luigi, Giunta, Emilio Francesco, De Falco, Vincenzo, Ciardiello, Davide, Belli, Valentina, Cardone, Claudia, Matrone, Nunzia, Poliero, Luca, Tirino, Virginia, Napolitano, Stefania, Della Corte, Carminia, Selvaggi, Francesco, Papaccio, Gianpaolo, Troiani, Teresa, Morgillo, Floriana, Desiderio, Vincenzo, Ciardiello, Fortunato, Martinelli, Erika |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7789007/ https://www.ncbi.nlm.nih.gov/pubmed/33407715 http://dx.doi.org/10.1186/s13046-020-01811-8 |
Ejemplares similares
-
Antitumor efficacy of triple monoclonal antibody inhibition of epidermal growth factor receptor (EGFR) with MM151 in EGFR-dependent and in cetuximab-resistant human colorectal cancer cells
por: Napolitano, Stefania, et al.
Publicado: (2017) -
Dual inhibition of TGFβ and AXL as a novel therapy for human colorectal adenocarcinoma with mesenchymal phenotype
por: Ciardiello, Davide, et al.
Publicado: (2021) -
Present and future of metastatic colorectal cancer treatment: A review of new candidate targets
por: Martini, Giulia, et al.
Publicado: (2017) -
Pulmonary Large-Cell Neuroendocrine Carcinoma: From Epidemiology to Therapy
por: Fasano, Morena, et al.
Publicado: (2015) -
Role of HGF–MET Signaling in Primary and Acquired Resistance to Targeted Therapies in Cancer
por: Della Corte, Carminia Maria, et al.
Publicado: (2014)